Stable low-level expression of p21WAF1/CIP1 in A549 human bronchogenic carcinoma cell line-derived clones down-regulates E2F1 mRNA and restores cell proliferation control

Molecular Cancer

Volumn 5, Issue , 2006, Pages

  Graves, Timothy G ^a   Harr, Michael W ^a   Crawford, Erin L ^a   Willey, James C ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 1; MESSENGER RNA; TRANSCRIPTION FACTOR E2F1; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; E2F1 PROTEIN, HUMAN; MYC PROTEIN; MYC PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE PARAMETERS; CELL CYCLE S PHASE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA CONTENT; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG CARCINOMA; MOLECULAR CLONING; OPEN READING FRAME; PHASE TRANSITION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; BRONCHUS; CELL CLONE; CELL TRANSFORMATION; EPITHELIUM CELL; GENETICS; METABOLISM; TUMOR CELL LINE;

BRONCHI; CARCINOMA, BRONCHOGENIC; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CLONE CELLS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; E2F1 TRANSCRIPTION FACTOR; EPITHELIAL CELLS; HUMANS; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 33144477785     PISSN: 14764598     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-4598-5-1     Document Type: Article

References (50)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer Statistics, 2003. CA A Cancer Journal for Clinicians 2003, 53:5-26.
2. Willey JC, Crawford EL, Jackson CM, Weaver DA, Hoban JC, Khuder SA, DeMuth JP: Expression measurement of many genes simultaneously by quantitative RT-PCR using standardized mixtures of competitive templates. American Journal of Respiratory Cell and Molecular Biology 1998, 19:6-17.
3. Willey JC, Crawford EL, Knight CA, Warner KA, Motten CR, Herness Peters E, Zahorchak RJ, Graves TG, Weaver DA, Bergman JR, Vondracek M, Grafstrom RC: Use of standardized mixtures of internal standards in quantitative RT-PCR to ensure quality control and develop a standardized gene expression database. A-Z of Quantitative PCR 2004:545-572.
4. Willey JC, Knight CR, Crawford EL, Olson DE, Hammersley J, Yoon Y, Sharief I: Use of standardized reverse transcription-polymerase chain reaction and the standardized expression measurement center in multi-institutional trials to develop meaningful lung cancer classification based on molecular genetic criteria. Chest 2004, 125:155S-156S.
5. Crawford EL, Khuder SA, Durham SJ, Frampton M, Utell M, Thilly WG, Weaver DA, Ferencak WJ, Jennings CA, Hammersley JR, Olson DA, Willey JC: Normal bronchial epithelial cell expression of glutathione transferase PI, glutathione transferase M3, and glutathione peroxidase is low in subjects with bronchogenic carcinoma. Cancer Research 2000, 60(6):1609-1618.
6. DeMuth JP, Jackson CM, Weaver DA, Crawford EL, Durzinsky DS, Durham SJ, Zaher A, Phillips ER, Khuder SA, Willey JC: The gene expression index c-myc × E2FI/p21 is highly predictive of malignant phenotype in human bronchial epithelial cells. American Journal of Respiratory Cell and Molecular Biology 1998, 19:18-24.
7. Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC: ABCC5, ERCC2, XPA and XRCC I transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Molecular Cancer 2005, 4(1):.
8. Warner KA, Crawford EL, Zaher A, Coombs RJ, Elsamaloty H, Roshong-Denk SL, Sharief I, Amurao Y, Yoon Y, Al-Astal AY, Assaly RA, Hernandez DA, Graves TG, Knight CR, Harr MW, Sheridan TB, DeMuth JP, Zahorchak RJ, Hammersley JR, Olson DE, Durham SJ, Willey JC: The c-myc × E2FI/p21 interactive gene expression index augments cytomorphologic diagnosis of lung cancer in fine-needle aspirate specimens. Journal of Molecular Diagnosis 2003, 5:176-183.
9. wafl/cipl among human bronchogenic carcinomas. Molecular Cancer 2005, 4(23):.
10. Lu W, Lin J, Chen J: Expression of p 14ARF overcomes tumor resistance to p53. Cancer Research 2002, 62(5):1305-1310.
11. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Experimental Cell Research 1994, 211:90-98.
12. Sheaff RJ, Singer JD, Swanger J, Smitherman M, Roberts JM, Clurman BE: Proteasomal turnover of p21cip I does not require p21Cip I ubiquitination. Molecular Cell 2000, 5:403-410.
13. EI-Diery WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW, Vogelstein B: WAFI, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
14. Gu Y, Turek CW, Morgan DO: Inhibition of CDK2 activity in vivo by an associated 20 K regulatory subunit. Nature 1993, 366:707-710.
15. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip I is a potent inhibitor of G I cyclin-dependent kinases. Cell 1993, 75:805-816.
16. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 1993, 366:701-704.
17. Nakanishi M, Kaneko Y, Matsushime H, Ikeda K: Direct interaction of p21 cyclin-dependent kinase inhibitor with the retinoblastoma tumor suppressor protein. Biochemical and Biophysical Research Communications 1999, 263:35-40.
18. Ando T, Kawabe T, Ohara H, Ducommun B, Itoh M, Okamoto T: Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. The Journal of Biological Chemistry 2001, 276(46):42971-42977.
19. Chen J, Jackson PK, Kirschner MW, Dutta A. Separate domains of p21 involved in the inhibition of cdk kinase and PCNA. Nature 1995, 374:386-388.
20. Waga S, Hannon GJ, Beach D, Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994, 369:574-578.
21. Kearsey JM, Coates PJ, Prescott AR, Warbrick E, Hall PA: Gadd45 is a nuclear cell cycle regulated protein which interacts with p21 Cip I. Oncogene 1995, 11(9):1675-1683.
22. Vairapandi M, Balliet AG, Fornace AJ Jr, Hoffman B, Liebermann DA: The differentiation primary response gene MyD 118, related to GADD45, encodes for a nuclear protein which interacts with PCNA and p21WAFI/ CIPI. Oncogene 1996, 12(12):2579-2594.
23. Chan TA, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B: Cooperative effects of genes controlling the G2/M checkpoint. Genes and Development 2000, 14(13):1584-1588.
24. Li R, Waga S, Hannon GJ, Beach D, Stillman B: Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994, 371:534-537.
25. Gartel AL, Tyner AL: Transcriptional regulation of the p21 (WAFI/CIPI) gene. Experimental Cell Research 1999, 246(2):280-289.
26. Dulic V, Kaufmann WK, Wilson SJ, Tisty TD, Lees E, Harper JW, Elledge SJ, Reed SI p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G I arrest. Cell 1994, 76:1013-1023.
27. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
28. Lechner JF, Haugen A, McClendon IA, Shamsuddin AM: Induction of squamous differentiation of normal human bronchial epithelial cells by small amounts of serum. Differentiation 1984, 25:229-237.
29. Dimova DK, Dyson NJ: The E2F transcriptional network: old acquaintances with new faces. Oncogene 2005, 24:2810-2826.
30. Mason SL, Loughran O, La Thangue NB: p 14(ARF) regulates E2F activity. Oncogene 2002, 21(27):4220-4230.
31. Weber JDTL, Roussel MF, Sherr CJ, Bar-Sagi D: Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biology 1999, 1(1):20-26.
32. Araki K, Nakajima Y, Eto K, Ikeda MA: Distinct recruitment of E2F family members to specific E2F-binding sites mediates activation and repression of the E2FI promoter. Oncogene 2003, 22:7632-7641.
33. Ishida S, Huang E, Zuzan H, Spang R, Leone G, West M, Nevins JR: Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Molecular Cell Biology 2001, 21(14):4684-4699.
34. Wafl/Cip1. Oncogene 1999, 18:5381-5392.
35. Rhee K, Ma T, Thompson EA: The macromolecular state of the transcription factor E2F and glucocorticoid regulation of cmyc transcription. Journal of Biological Chemistry 1994, 269:17035-17042.
36. Kitaura H, Shinshi M, Uchikowski Y, Ono T, Tsurimoto T, Yoshikawa H, Iguchi-Ariga SMM, Ariga H: Reciprocal regulation via protein-protein interaction between c-Myc and p21(cipI/wafl/sdi I) in DNA replication and transcription. Journal of Biological Chemistry 2000, 275(21):10477-10483.
37. Zajac-Kaye M: Myc oncogene: a key component in cell cycle regulation and its implication for lung cancer. Lung Cancer 2001, 34:S43-S46.
38. Boxer RB, Jang JW, Sintasath L, Chodosh LA: Lack of sustained regression of c-MYC- induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 2004, 6(6):577-586.
39. Ritt MG, Mayor J, Wojcieszyn J, Smith R, Barton CL, Modiano JF: Sustained nuclear localization of p21/WAF-I upon growth arrest induced by contact inhibition. Cancer Letters 2000, 158(1):73-84.
40. Zhong Y, Lopez-Barcons L, Haigentz M Jr, Ling YH, Perez-Soler R: Exogenous expression of H-cadherin in CHO cells regulates contact inhibition of cell growth by inducing p21 expression. International Journal of Oncology 2004, 24(6):1573-1579.
41. Huang ZY, Wu Y, Hedrick N, Gutmann DH: T-cadherin-mediated cell growth regulation involves G2 phase arrest and requires p21 (CIP I/WAF I) expression. Molecular and Cellular Biology 2003, 23(2):566-578.
42. Tsuji T, Aoshiba K, Nagai A: Cigarette smoke induces senescence in alveolar epithelial cells. American Journal of Respiratory Cell and Molecular Biology 2004, 31(6):643-649.
43. Reynisdottir I, Polyak K, Iavarone A, Massague J: Kip/Cip and INK4 cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes and Development 1995, 9:1831-1845.
44. Katakura Y, Nakata E, Tabira Y, Miura T, Teruya K, Tsuchiya T, Shirahata S: Decreased tumorigenicity in vivo when transforming growth factor beta treatment causes cancer cell senescence. Bioscience, Biotechnology, Biochemistry 2003, 67(4):815-821.
45. Toyama T, Sasaki Y, Horimoto M, Iyoda K, Yakushijin T, Ohkawa K, Takehara T, Kasahara A, Araki T, Hori M, Hayashi N: Ninjurin I increases p21 expression and induces cellular senescence in human hepatoma cells. Journal of Hepatology 2004, 41(4):637-643.
46. Willey JC, Moser CE Jr, Lechner JF, Harris CC: Differential effects of 12-O-tetradecanoylphorbol-13-acetate on cultured normal and neoplastic human bronchial epithelial cells. Cancer Research 1984, 44:5124-5126.
47. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1993, 62: 156-159.
48. Willey JC, Coy EL, Frampton MW, Torres A, Apostolakos MJ, Hoehn G, Schuermann WH, Thilly WG, Olson DE, Hammersley JR, Crespi CL, Utell MJ: Quantitative RT-PCR measurement of p450 1A1, 1B1, and 2B7, microsomal epoxide hydrolase, and NADPH oxidoreductase expression in lung cells of smokers and non-smokers. American Journal of Respiratory Cell and Molecular Biology 1997, 17:114-124.
49. Willey JC, Crawford EL, Knight CR, Warner KA, Motten CA, Herness EA, Zahorchak RJ, Graves TG: Standardized RT-PCR and the standardized expression measurement center. Methods in Molecular Biology: Gene Expression Profiling: Methods and Protocols 2004, 258:13-41.
50. Vindelov: A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1982, 3(5):323-327.